Proposal for MSDC-0602K (Cirius Therapeutics; PPARγ modulating MPC inhibitor)

Overview of Therapeutic Candidate:
MSDC-0602K is a synthetic small‐molecule therapeutic candidate developed by Cirius Therapeutics that belongs to the thiazolidinedione (TZD) class but is specifically engineered to spare direct activation of the peroxisome proliferator-activated receptor γ (PPARγ). Unlike classical TZDs such as pioglitazone and rosiglitazone, which were initially discovered through animal phenotypic screens and exert their insulin-sensitizing effects predominantly via PPARγ agonism, MSDC-0602K has been designed to target the mitochondrial pyruvate carrier (MPC) with minimal PPARγ engagement. As a PPARγ-sparing TZD, it modulates mitochondrial pyruvate flux and cellular energy metabolism without inducing the adverse effects (for example, fluid retention, weight gain, and bone loss) that are typically associated with full PPARγ activation (Colca, 2015, pp. 5–6; Huang et al., 2024, pp. 11–12). The molecule is a second-generation TZD analog developed using medicinal chemistry approaches that focus on structural modifications—such as retention of an asymmetric carbon at the 5-position of the TZD ring but with chemical modifications that reduce PPARγ affinity—while preserving the capability to inhibit MPC. In this context, the compound’s discovery arose from investigations into the metabolic actions of first-generation TZDs that indicated a mitochondrial component to their insulin-sensitizing effects; subsequent research identified the MPC—composed of MPC1 and MPC2—as a critical target mediating these benefits (Colca et al., 2017, pp. 1–2; Chen et al., 2022, pp. 14–15). As such, MSDC-0602K falls within the subclass of “mTOT” modulators that aim to improve systemic metabolism through direct modulation of mitochondrial substrate handling rather than through conventional nuclear receptor pathways.

Therapeutic History:
Historically, the TZD class has been employed primarily in the management of type 2 diabetes mellitus (T2DM) owing to their insulin-sensitizing properties, with pioglitazone and rosiglitazone serving as prototypical agents. However, their clinical utility has been hindered by side effects resulting from PPARγ activation. In response, next-generation TZDs such as MSDC-0602K have been developed to retain the beneficial metabolic effects while minimizing PPARγ-mediated adverse events. Preclinical studies using rodent models, including diet-induced obese and db/db mice, have demonstrated that compounds like MSDC-0602K improve glycemic control, decrease hyperinsulinemia, reduce hepatic lipogenesis, and lower circulating liver enzymes—outcomes that are achieved predominantly via modulation of mitochondrial metabolism rather than through classical PPARγ agonism (Colca, 2015, pp. 6–8; Benova et al., 2022, pp. 1–2). In clinical settings, phase II and phase III trials have been conducted in patients with nonalcoholic steatohepatitis (NASH) and T2DM, evaluating endpoints such as improvements in hepatic histology, reductions in HbA1c, and better glycemic parameters with a favorable safety profile (ClinicalTrials.gov, 2016; ClinicalTrials.gov, 2022). Although there is substantial clinical data supporting its use in T2DM and NASH, there is not yet any published trial or extensive preclinical data specifically addressing its use in Polycystic Ovary Syndrome (PCOS) or similar reproductive metabolic disorders. Nevertheless, PCOS shares a central pathophysiological element—in particular, insulin resistance—with T2DM, which forms part of the rationale for repurposing MSDC-0602K toward PCOS therapeutic approaches (Yuan et al., 2022, pp. 1–3; Colca et al., 2017, pp. 2–4).

Mechanism of Action:
MSDC-0602K operates primarily through the inhibition of the mitochondrial pyruvate carrier (MPC), which is essential for transporting pyruvate from the cytosol into the mitochondrial matrix where it serves as a critical substrate for the tricarboxylic acid (TCA) cycle and subsequent adenosine triphosphate (ATP) production. Under normal conditions, pyruvate imported via the MPC is metabolized either by conversion to acetyl-CoA via pyruvate dehydrogenase or to oxaloacetate by pyruvate carboxylase—routes that are pivotal for gluconeogenesis and lipogenesis in hepatocytes (Colca, 2015, pp. 9–11; McCommis & Finck, 2023, pp. 4–5). By partially blocking MPC-mediated pyruvate uptake, MSDC-0602K induces a metabolic shift that reduces substrate flow into mitochondrial oxidation pathways. This results in a decrease in hepatic gluconeogenesis as less pyruvate is available for conversion into glucose precursors. Additionally, this forced alteration of pyruvate flux is thought to generate a compensatory increase in cytosolic redox states, with subsequent activation of the energy-sensing enzyme AMP-activated protein kinase (AMPK) (Ferguson et al., 2023, pp. 18–22; Huang et al., 2024, p. 16). AMPK is well known for its role in enhancing insulin signaling via downstream activation of the phosphoinositide-3 kinase (PI3K)/Akt pathway. In several preclinical models, activation of AMPK by compounds that inhibit MPC has correlated with improved insulin sensitivity and enhanced glucose uptake in peripheral tissues (Kamm et al., 2020, pp. 11–14; Colca et al., 2017, pp. 1–2). Beyond these primary actions, TZD-like molecules such as MSDC-0602K have been associated with modulation of mitochondrial function, including alterations in substrate preferences for oxidation (e.g., a shift from glucose oxidation to enhanced lipid oxidation) and reductions in the production of mitochondrial reactive oxygen species (ROS). Such changes can lead to improvements in cellular energy homeostasis and reduced metabolic inflammation. Importantly, MSDC-0602K is classified as “PPARγ-sparing” because it demonstrates substantially lower direct binding to PPARγ compared to classical TZDs, thereby mitigating the transcriptional activation of adipogenic genes and the subsequent unwanted side effects like fluid retention and weight gain (Colca, 2015, p. 12; Huang et al., 2024, pp. 11–12). At the molecular level, the inhibition of MPC by MSDC-0602K decreases the availability of pyruvate for mitochondrial oxidation, thereby limiting the TCA cycle flux and lowering the production of acetyl-CoA and ATP through oxidative phosphorylation. This metabolic stress, in turn, increases the AMP/ATP ratio, activating AMPK. The enhanced AMPK signaling upregulates glucose transporter translocation (e.g., of GLUT4) to the cell surface and improves downstream insulin receptor signaling through the PI3K/Akt cascade (Ferguson et al., 2023, pp. 18–22; McCommis & Finck, 2023, pp. 14–15). This provides a mechanistic underpinning for the observed improvements in insulin sensitivity in animal models and clinical studies. Moreover, studies have indicated that MPC modulation can influence the phosphorylation status of enzymes such as branched‐chain ketoacid dehydrogenase (BCKDH) and ATP citrate lyase (ACLY), though these aspects are more directly studied in the context of diabetes and nonalcoholic fatty liver disease (NAFLD) than in ovarian tissue contexts (Kamm et al., 2020, pp. 14–17; Ferguson et al., 2023, pp. 12–14).

Expected Effect:
The hypothesis driving the repurposing of MSDC-0602K for PCOS is that by inhibiting the MPC in ovarian theca cells, the drug will increase cytosolic redox states and activate AMPK, thereby enhancing downstream insulin receptor signaling (via the PI3K/Akt pathway) and restoring efficient glucose uptake. In PCOS, dysregulation of insulin signaling in ovarian cells is a key pathophysiological feature that contributes to hyperandrogenism, aberrant folliculogenesis, and metabolic dysfunction. The expected result in the assay is that treatment of theca cell models with MSDC-0602K will lead to an increase in the AMP/ATP ratio, elevated phosphorylation of AMPK, and, subsequently, an enhanced PI3K/Akt signal, all of which are pivotal for improving insulin sensitivity. Evidence from rodent models of T2DM and NASH—conditions that share underlying insulin resistance with PCOS—demonstrate that MPC inhibition by MSDC-0602K reverses hyperinsulinemia and reduces lipotoxicity, thereby normalizing insulin signaling cascades (Kamm et al., 2020, pp. 4–8; Colca et al., 2017, pp. 2–4). Although specific data in ovarian cell types are not yet published, it is reasonable to project from the hepatocyte and skeletal muscle data that in the ovarian theca cells, enhanced cytosolic redox status would counteract abnormal metabolic conditions. Furthermore, the PI3K/Akt pathway is known to be expressed in theca cells and plays an essential role in mediating insulin effects on these cells, including the regulation of steroidogenesis and glucose uptake. Therefore, in an in vitro assay, one would expect to observe improved insulin-mediated glucose uptake and normalization of insulin receptor substrate (IRS) signaling, as evidenced by enhanced Akt phosphorylation and increased GLUT transporter mobilization (Colca, 2015, pp. 9–11; Ferguson et al., 2023, pp. 9–12). In addition to the activation of AMPK, improved mitochondrial function and balanced substrate utilization may also reduce lipotoxic stress in ovarian tissues, potentially contributing to the re-establishment of normal cellular function and hormone synthesis pathways. These mechanisms collectively would work to restore the cellular metabolic environment, thereby ameliorating insulin resistance—a central feature of PCOS.

Overall Evaluation:
The potential of MSDC-0602K as a therapeutic candidate for PCOS is supported by a robust mechanistic rationale, a favorable preclinical and early clinical safety profile, and a known ability to improve insulin sensitivity through mitochondrial modulation while avoiding the side effects commonly associated with classical TZDs. One significant strength of MSDC-0602K is its dual capacity to modulate mitochondrial pyruvate metabolism and activate the AMPK signaling pathway, thereby enhancing insulin receptor signaling without provoking the PPARγ-related adverse effects. This is particularly relevant in PCOS, wherein insulin resistance directly contributes to hyperandrogenism and reproductive dysfunction. The extensive preclinical data demonstrating improved glycemic control, reduced hepatic steatosis, decreased hyperinsulinemia, and amelioration of lipotoxicity in established rodent models of T2DM and NAFLD lend strong support to its anticipated effectiveness in other insulin-resistant states such as PCOS (Colca, 2015, pp. 6–8; Benova et al., 2022, pp. 12–14).
Another strength is the existence of clinical data from phase II and phase III trials in metabolic diseases, which establish pharmacokinetics, dosing strategies, and a safety profile that expedite repurposing for additional indications (ClinicalTrials.gov, 2016; ClinicalTrials.gov, 2022). The well-characterized mechanism of action—particularly the inhibition of MPC leading to increased cytosolic redox states and subsequent AMPK activation—provides a clear biological pathway that is likely to be relevant in the ovarian theca cell context. The PI3K/Akt pathway, which is critical in transducing insulin signals, is well documented in ovarian tissues, and improvements in this signaling cascade have the potential to restore normal glucose uptake and steroidogenesis (Ferguson et al., 2023, pp. 18–22; McCommis & Finck, 2023, pp. 14–15).

However, several weaknesses and challenges must be considered. First, while the insulin-sensitizing effects of MSDC-0602K are well documented in hepatic and muscle tissues, direct evidence of its effects in ovarian cell models—specifically in the context of PCOS—remains sparse. Dedicated studies on the expression and function of MPC and the downstream signaling pathways in PCOS theca cells are needed to confirm that the mechanisms observed in other tissues translate effectively to the ovarian microenvironment. Second, the balance between therapeutic inhibition of MPC and the possible deleterious effects on mitochondrial energy production needs further exploration. Although partial inhibition may beneficially shift substrate metabolism, excessive inhibition in tissues with high energy demands could potentially lead to unintended metabolic stress or compensatory mechanisms that mitigate the desired benefit. Third, while the compound has a favorable safety profile compared to classical TZDs, long-term safety specifically in reproductive-aged women with PCOS will need to be carefully documented, particularly concerning potential impacts on ovarian function and fertility. Additionally, there remains a possibility that compensatory metabolic pathways may be activated in response to chronic MPC inhibition, which could attenuate the sustained efficacy of the intervention over time. Lastly, while the clinical trials in T2DM and NASH provide important proof-of-concept data, the pathophysiological environment in PCOS—with its unique interplay of hyperinsulinemia, hyperandrogenism, and chronic low-grade inflammation—may require adjunct strategies alongside MPC inhibition to fully restore normal ovarian function (Yuan et al., 2022, pp. 1–3; Colca et al., 2017, pp. 2–4).

In summary, MSDC-0602K emerges as a very promising candidate for repurposing in PCOS due to its ability to modulate mitochondrial pyruvate metabolism, thereby activating AMPK and enhancing insulin signaling without the collateral side effects of direct PPARγ activation. The hypothesis that MDC-0602K will improve insulin receptor downstream PI3K/Akt signaling in PCOS theca cells by shifting cytosolic redox balance is well grounded in the extensive biomedical literature on its effects in T2DM and NASH. The compound’s known pharmacokinetics, safety profile, and mechanism of action provide a solid foundation for further preclinical exploration in ovarian cell models and eventual clinical trials focused on PCOS. Nonetheless, additional investigations are warranted to determine the precise metabolic and hormonal effects in ovarian tissues, to optimize dosing specific for reproductive indications, and to ensure that long-term administration in women produces sustained metabolic and reproductive improvements without adverse consequences. Overall, based on current literature evidence (Colca, 2015, pp. 5–6; Ferguson et al., 2023, pp. 18–22; Kamm et al., 2020, pp. 11–14; McCommis & Finck, 2023, pp. 14–15; Huang et al., 2024, pp. 11–12; ClinicalTrials.gov, 2016), MSDC-0602K holds significant potential as a repurposed drug candidate for treating the metabolic dysfunction observed in PCOS, although further focused studies in ovarian-specific systems are essential to validate this therapeutic strategy thoroughly.

References
Benova, A., Ferencaková, M., Bardová, K., Funda, J., Procházka, J., Špoutil, F., Cajka, T., Dzubánová, M., Balcaen, T., Kerckhofs, G., Willekens, W., van Lenthe, G. H., Alquicer, G., Pecinová, A., Mráček, T., Horáková, O., Rossmeisl, M., Kopecký, J., & Tencerová, M. (2022). Novel thiazolidinedione analog reduces a negative impact on bone and mesenchymal stem cell properties in obese mice compared to classical thiazolidinediones. Molecular Metabolism, 65, 101598. https://doi.org/10.1016/j.molmet.2022.101598

Chen, J. Y. S., Chua, D., Lim, C. O., Ho, W. X., & Tan, N. S. (2022). Lessons on drug development: A literature review of challenges faced in nonalcoholic fatty liver disease clinical trials. International Journal of Molecular Sciences, 24, 158. https://doi.org/10.3390/ijms24010158

ClinicalTrials.gov. (2016). A study to evaluate the safety, tolerability & efficacy of MSDC-0602K in patients with NASH. Retrieved from https://clinicaltrials.gov/ct2/show/NCT02784444

ClinicalTrials.gov. (2022). A study of MSDC-0602K to assess glycemic control and cardiovascular outcomes in patients with pre-T2D or T2D and NAFLD/NASH. Retrieved from https://clinicaltrials.gov/ct2/show/NCT03970031

Colca, J. R. (2015). The TZD insulin sensitizer clue provides a new route into diabetes drug discovery. Expert Opinion on Drug Discovery, 10(10), 1259–1270. https://doi.org/10.1517/17460441.2015.1100164

Colca, J. R., McDonald, W. G., McCommis, K. S., & Finck, B. N. (2017). Treating fatty liver disease by modulating mitochondrial pyruvate metabolism. Hepatology Communications, 1(3), 193–197. https://doi.org/10.1002/hep4.1036

Ferguson, D., Eichler, S. J., Yiew, N. K. H., Colca, J. R., Cho, K., Patti, G. J., Lutkewitte, A. J., McCommis, K. S., Niemi, N. M., & Finck, B. N. (2023). Mitochondrial pyruvate carrier inhibition initiates metabolic crosstalk to stimulate branched chain amino acid catabolism [Preprint]. bioRxiv. https://doi.org/10.1101/2022.05.11.491550

Huang, Y., Zhang, H., Peng, X., & Zhang, Q. (2024). Recent advances in mitochondrial pyruvate carrier inhibitors. Pharmaceutical Fronts, 6, e221–e236. https://doi.org/10.1055/s-0044-1788072

Kamm, D. R., Pyles, K. D., Sharpe, M. C., Healy, L., Colca, J. R., & McCommis, K. S. (2020). MSDC-0602K, a novel insulin-sensitizer, improves insulinemia and fatty liver disease alone and in addition to liraglutide in mice [Preprint]. bioRxiv. https://doi.org/10.1101/2020.12.10.420190

McCommis, K. S., & Finck, B. N. (2023). The hepatic mitochondrial pyruvate carrier as a regulator of systemic metabolism and a therapeutic target for treating metabolic disease. Biomolecules, 13(2), 261. https://doi.org/10.3390/biom13020261

Yuan, L., McCommis, K. S., & Neuschwander-Tetri, B. A. (2022). Two faces of pioglitazone: Sorting out the roles of its PPARγ binding versus mitochondrial pyruvate carrier inhibition is not so simple. Hepatology Communications, 6(12), 3003–3005. https://doi.org/10.1002/hep4.1773
